They accuse their neurologists and the French drug manufacturer Sanofi, which produces Depakine, of failing to warn them about the risks to the fetus, according to reports published on Le Matin Dimanche and SonntagsZeitung.
Depakine is still widely used today to treat epilepsy and migraines. Scientists have established that the sodium valproate contained in the drug creates psychomotor, cognitive and mental development disorders in 30 to 40% of cases.
The Swiss expecting mothers were not made aware of these dangers. A warning from agency for therapeutic products, Swissmedic, came to late.
In Switzerland, 39 children have been born with brain damage in connection to Depakine use, according to a report commissioned by the government.
Thierry Buclin, a professor of clinical pharmacology at the University Hospital of Lausanne suspects the actual figure is much higher.
The professors, who was quoted in the media reports, says the government study is incomplete. It does not consider the transgenerational effect of Depakin which has been brought to light by recent scientific studies.
The controversial drug has been authorised in Switzerland since the 1970s. Such side effects were not mentioned in the package leaflet until 2015.
In neighbouring France, as many as 6,500 children have been negatively affected by Depakine. The victims launched a collective action against Sanofi at the end of 2016 to obtain compensation.
The first complaint was made in Switzerland in 2017 by a woman who had been using the drug since adolescence and even had her dosage raised by her neurologist during one of her pregnancies. She gave birth to two children who suffer from severe cognitive disorders and autism.
Young undocumented migrants gain easier access to vocational training
This content was published on
Rejected asylum-seekers and young undocumented migrants in Switzerland will have easier access to basic vocational training from June 1.
Migration: Swiss government wants to shorten reunification period for families
This content was published on
Family members of people temporarily admitted to Switzerland should in future be able to join them after two years instead of three.
This content was published on
2023 was a record year for the Rhaetian Railway in several respects. Never before has the narrow-gauge railway in Graubünden, eastern Switzerland, transported so many passengers and cars.
Swiss CFOs much more optimistic despite global uncertainty
This content was published on
The main concerns of business leaders in Switzerland are geopolitical uncertainty and the important trading partners Germany and China.
Record organ donation in Switzerland despite high rejection rates
This content was published on
More organ donations were recorded in Switzerland in 2023 than ever before. This was despite a high rejection rate of 58% by surviving relatives.
This content was published on
Seven years after the death of record-breaking Swiss mountain climber Ueli Steck, his estate is going to the Alpine Museum of Switzerland in Bern.
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.
Read more
More
Novartis and Microsoft to develop drugs using AI
This content was published on
Novartis and Microsoft have signed a five-year partnership aimed at transforming the Basel-based pharma’s business using AI.
Gaps found in opioid prescription oversight in Switzerland
This content was published on
In the wake of the opioid crisis in the US, some medical professionals in Switzerland are warning about over-prescription of oxycodone drugs.
Swiss pharmaceutical firm lets dogs die cruel death
This content was published on
Dogs are being left to die in agony in Germany after lab testing for the Swiss pharma company Inthera Bioscience, says a report.
You can find an overview of ongoing debates with our journalists here . Please join us!
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.